

5

USE OF MONOCLONAL ANTIBODIES THAT DEFINE
UNIQUE MENINGOCOCCAL B EPITOPES IN THE
PREPARATION OF VACCINE COMPOSITIONS

Abstract of the Disclosure

10 Novel bactericidal antibodies against *Neisseria meningitidis* serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are 15 used to identify molecular mimetics of unique epitopes found on MenB or *E. coli* K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used 20 to prevent MenB or *E. coli* K1 disease without the risk of evoking autoantibody.

25

30

35